Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATR 1072 in PRKAG2 Syndrome
NCT07738107Phase 2Recruiting
- Sponsor
- Atrium Therapeutics
- Start
- Sep 2026
- Primary completion
- May 2028
- Countries
- 1
01
Overview
Phase 2, open-label trial of ATR-1072 in PRKAG2 syndrome (PS) (2 arms), sponsored by Atrium Therapeutics. Primary endpoint: Incidence of treatment-emergent adverse events at 48 weeks. Started Sep 2026; status: recruiting.
02
Drugs
ATR-1072
03
Conditions
PRKAG2 syndrome (PS)
Beyond the preview
Go deeper on NCT07738107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07738107.